Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces

Journal of Chromatography B: Biomedical Applications

Volumn 712, Issue 1-2, 1998, Pages 225-235

  Sparreboom, Alex ^a   De Bruijn, Peter ^a   De Jonge, Maja J A ^a   Loos, Walter J ^a   Stoter, Gerrit ^a   Verweij, Jaap ^a   Nooter, Kees ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Irinotecan

Indexed keywords

7 ETHYL 10 [4 N (5 AMINOPENTANOIC ACID) 1 PIPERIDINO]CARBONYLOXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN BETA GLUCURONIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; IRINOTECAN; RPR 121056A; UNCLASSIFIED DRUG;

ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG FECES LEVEL; DRUG SCREENING; DRUG URINE LEVEL; HUMAN; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

CAMPTOTHECIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; FECES; GLUCURONATES; HUMANS; PILOT PROJECTS; REPRODUCIBILITY OF RESULTS;

EID: 0032493799     PISSN: 15726495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4347(98)00147-9     Document Type: Article

References (28)

1. Sawada S., Okajima S., Aiyama R., Nokata K., Furuta T., Yokokura T., Sugino E., Yamaguchi K., Miyasaka T. Chem. Pharm. Bull. 39:1991;1446.
2. Kunimoto T., Nitta K., Tanaka Y., Uehara N., Baba H., Takeuchi M., Yokokura T., Sawada S., Miyasaka T., Mutai M. Cancer Res. 47:1987;5944.
3. Tsuruo T., Matzusaki T., Matsushita M., Saito H., Yokokura T. Cancer Chemother. Pharmacol. 21:1988;71.
4. Creemers G.J., Lund B., Verweij J. Cancer Treat. Rev. 20:1994;73.
5. Gerrits C.J.H., de Jonge M.J.A., Schellens J.H.M., Verweij J. Br. J. Cancer. 76:1997;952.
6. Kaneda N., Nagata H., Furuta T., Yokokura T. Cancer Res. 50:1990;1715.
7. Kaneda N., Yokokura T. Cancer Res. 50:1990;1721.
8. Kawato Y., Aonuma M., Hirota Y., Kuga H., Sato K. Cancer Res. 51:1991;4187.
9. Tsuji T., Kaneda N., Kado K., Yokokura T., Yoshimoto T., Tsuru D. J. Pharmacobio.-Dyn. 14:1991;341.
10. Rivory L.P., Bowles M.R., Robert J., Pond S.M. Biochem. Pharmacol. 52:1996;1103.
11. Atsumi R., Okazaki O., Hakusui H. Biol. Pharm. Bull. 18:1995;1024.
12. Atsumi R., Suzuki W., Hakusui H. Xenobiotica. 21:1991;1159.
13. Gupta E., Lestingi T.M., Mick R., Ramirez J., Vokes E.E., Ratain M.J. Cancer Res. 54:1994;3723.
14. Lokiec F., Canal P., Gay C., Chatelut E., Armand J.P., Roché H., Bugat R., Gonçalvès E., Mathieu-Boué A. Cancer Chemother. Pharmacol. 36:1995;79.
15. Rivory L.P., Robert J. Cancer Chemother. Pharmacol. 36:1995;176.
16. Haaz M.C., Rivory L.P., Jantet S., Ratanasavanh D. Pharmacol. Toxicol. 80:1997;91.
17. Iyer L., King C.D., Whitington P.F., Green M.D., Roy S.K., Tephly T.R., Coffman B.L., Ratain M.J. J. Clin. Invest. 101:1998;847.
18. Takasuna K., Hagiwara T., Hirohashi M., Kato M., Nomura M., Nagai E., Yokoi T., Kamataki T. Cancer Res. 56:1996;3752.
19. Rivory L.P., Riou J.F., Haaz M.C., Sable S., Vuilhorgne M., Commerçon A., Pond S.M., Robert J. Cancer Res. 56:1996;3689.
20. Haaz M.C., Rivory L.P., Riché C., Vernillet L., Robert J. Cancer Res. 58:1998;468.
21. Lokiec F., Monegier du Sorbier B., Sanderink G.J. Clin. Cancer Res. 2:1996;1943.
22. de Bruijn P., Verweij J., Loos W.J., Nooter K., Stoter G., Sparreboom A. J. Chromatogr. B. 698:1997;277.
23. Bourzat J.D., Vuilhorgne M., Rivory L.P., Robert J. Tetrahedron Lett. 37:1996;6327.
24. de Jonge M.J.A., Sparreboom A., Planting A.S.T., van der Burg M.E.L., de Bruijn P., Brouwer E., van Beurden V., van Duijn M.R., Jacques C., Verweij J. Eur. J. Cancer. 33(S8):1997;S251.
25. Shah V.P., Midha K.K., Dighe S., McGilveray I.G., Skelly J.P., Yacobi A., Layloff T., Viswanathan C.T., Cook C.E., McDowall R.D., Pittman K.A., Spector S. J. Pharm. Sci. 81:1992;309.
26. Rivory L.P., Robert J. J. Chromatogr. B. 661:1994;133.
27. Li Y.-F., Zhang R. J. Chromatogr. B. 686:1996;257.
28. Rivory L.P., Haaz M.C., Canal P., Lokiec F., Armand J.P., Robert J. Clin. Cancer Res. 3:1997;1261.